All News

RA ILD RTX lung

Rituximab vs. JAK inhibitors in Rheumatoid Lung Disease

d Jack Cush, MD

There are no current FDA approved therapies for rheumatoid arthritis associated interstitial lung disease (RA-ILD) or bronchiectasis, but a recent retrospective cohort study showed equivalent outcomes when RA-ILD patients were treated with either rituximab or janus kinase inhibitors.

Read Article
RheumNow Podcast square

RheumNow Podcast – Great Associations (3.19.2021)

d Jack Cush, MD

Dr. Jack Cush rants on the journal reports, news and FDA actions featured this past week on RheumNow.com.

Read Article
Super RA superman

Are You a Super Rheum?

d Jack Cush, MD

Several weeks ago, at the Rheumatology Winter Clinical Symposia, an interesting debate between Drs. Orrin Troum and Marty Bergman hashed over the concept of whether rheumatologists should sub-specialize with a practice, research or career devoted to one disease ("Super Rheum"), or be "selective" about what disorders and diseases they would treat or just be a generalist. 

Read Article
hudsonpsoriasis.jpg

Apremilast Equals MTX in Palmoplantar Psoriasis

d Jack Cush, MD

Palmoplantar psoriasis (PPP) is a therapeutically challenging variant of psoriasis; nonetheless, a prospective, randomized, active-controlled trial from India suggests that apremilast is effective and safe in patients with PPP.

Read Article
hip.fracture.jpg

Potent Topical Corticosteroids and the Risk of Osteoporotic Fractures

d Jack Cush, MD

JAMA Dermatology has published a Danish national cohort study showing that potent topical corticosteroid use was associated with an increased risk of osteoporosis and major osteoporotic fractures with a dose-response association for cumulative use.

Read Article
NAFLD, NASH and Risks with DMARDs and MTX https://t.co/LYV9WycEjz https://t.co/Vx0jvhjCsd

Links:

Dr. John Cush RheumNow ( View Tweet)
Kiniksa announced Arcalyst (rilonacept) has been FDA-approved for the treatment of recurrent pericarditis. Rilonacept, an IL-1 inhibitor, also FDA approved for CAPS (Cryopyrin-Assoc Periodic Syndr) & DIRA (Defic IL-1 Recept Antag) https://t.co/erpiyuhsAv https://t.co/xp764WkWEI

Links:

Dr. John Cush RheumNow ( View Tweet)

News Feature: MDA-5 Antibodies and Juvenile Dermatomyositis https://t.co/vxyXZyO0gs https://t.co/GgzhnhlmdR

Links:

Dr. John Cush RheumNow ( View Tweet)
SPIRIT‐P3 RCT treated biologic‐naive PsA with ixekizumab x36 wks; those w/ MDA x 3 mos were randomized to continue or withdraw IXE (blinded). There were significantly more relapses when IXE was stopped; most regained control when started https://t.co/lhQ8X1Ef48

Links:

Dr. John Cush RheumNow ( View Tweet)

RCT shows Stepped Exercise Program to be effective in Knee Osteoarthritis. VAMC study of 345 knee OA pts given either STEP-KOA (internet based progr) or an arthritis education (control). WOMAC scores at 9 mos were 6.8 points lower in the STEP-KOA group.https://t.co/EuoPyJkTif

Links:

Dr. John Cush RheumNow ( View Tweet)

There's still time to sign up. Attend RheumNow Live this weekend. We have a robust schedule planned with top professional. https://t.co/LJ3qClHTKh

Links:

Dr. John Cush RheumNow ( View Tweet)

Hydroxychloroquine studied vs Vitamin C (PBO) prophylaxis to households (n=671) exposed to COVID-19. 89% were COVD1-9 test neg at baseline. HCQ did not protect against progression to COVID (53 vs 45 events; adj HR, 1.10 [95% CI, 0.73 to 1.66]. A vit C Win! https://t.co/S5qjdIYaXq

Links:

Dr. John Cush RheumNow ( View Tweet)

The Reflecting Rheum: Top Publications from 2020 Covering SpA and Still’s Disease Sponsored by Novartis Medical Affairs Listen to a panel of experts share their views on top spondyloarthritis and Still’s disease publications from 2020. View Now: https://t.co/rxTAwQNalx https://t.co/y8wnHSmBug

Links:

Dr. John Cush RheumNow ( View Tweet)
Phase III RCT of apremilast showed no benefit in ankylosing spondylitis pts. 490 AS pts recv placebo or apremilast 20 mg or 30 mg bid 24 wks. The ASAS 20 was the same in all groups (PBO: 37%; 20 mg 35%; 30 mg 33). 2 yrs Xray changes were equal too. https://t.co/ILYtVMZp80

Links:

Dr. John Cush RheumNow ( View Tweet)

Concise overview of Ehlers-Danlos syndrome from Medscape...FYI https://t.co/acHSoEhVVF

Links:

Dr. John Cush RheumNow ( View Tweet)

News Feature: Enthesitis Responses to Secukinumab in Spondylitis Patients https://t.co/U7qfwwA2as https://t.co/lFa5LdfkIZ

Links:

Dr. John Cush RheumNow ( View Tweet)
Epi study of Scleritis in the UK (1997-2018) shows incidence declined from 4.23 to 2.79/100K persons/yr. Scleritis pts have 2 fold incr risk of IMIDs- esp GPA, Behçets Sjögrens, ReA, RA, SLE, Crohns, SLE & AS (OR 51 to >3). https://t.co/FzaCLRvmEX https://t.co/98M5o66fpD

Links:

Dr. John Cush RheumNow ( View Tweet)
Great full read NEJM review of Extrahepatic manifestations of Chronic HCV Infection; 1) mixed cryo vasculitis; 2)20-30% w/ HCV related Sicca (w/ SSA, SSB); 3) fatigue & FM; 4) AutoAbs: 70% RF+, <40% ANA+, 15% ACL Abs, 7% smooth muscle Abs https://t.co/YrIJbs8P8k

Links:

Dr. John Cush RheumNow ( View Tweet)

Charcot (neuropathic) arthritis: often manifests as exaggerated bony hypertrophy w/o joint pain. Common causes(sites): diabetes (TMT ankle), tabes dorsalis/syphilis (hip or knee), syringomyelia (Shoulders, elbows) . Also CPPD, steroids, alcohol, amyloid https://t.co/SrYYrVjSq3

Links:

Dr. John Cush RheumNow ( View Tweet)

BC Canada population study shows newly diagnosed #SLE patients (n=5,169) have a higher rate of 1st serious/sever infections (1.8-fold), and more total severe infections (2.1-fold) and infection-related mortality (1.6-fold) vs general population. https://t.co/acDk0WYSby

Links:

Dr. John Cush RheumNow ( View Tweet)

×